InterShunt Enrolls First Patient in New Heart Failure Study

Helping the heart heal itself — UK researchers lead new treatment effort

It’s a frightening statistic: someone in the U.S. has a heart attack every 40 seconds. For many Kentuckians, the risk is even higher due to widespread health challenges like obesity, smoking and chronic illness.

InterShunt Enrolls First Patient in New Heart Failure Study

Innovative procedure aims to ease symptoms and reduce hospitalizations ...

InterShunt Initiates Study Of Device For Heart Failure Treatment - Data Intelligence

Heart failure is a major cause of hospitalisation for adults above the age of 65 years. Credit: sasirin pamai / Shutterstock. InterShunt Technologies has initiated the EASE HF2 early feasibility study to assess the InterShunt percutaneous atrial shunt catheter (PAS-C) system, intended to alleviate symptoms of heart failure and enhance the quality of life for patients. The first procedure in the US using the device was performed at The Christ Hos…

InterShunt initiates study of device for heart failure treatment

InterShunt has initiated the EASE HF2 early feasibility study of the InterShunt percutaneous atrial shunt catheter (PAS-C) system.The post InterShunt initiates study of device for heart failure treatment appeared first on Medical Device Network.

Regeneron’s Heart Failure Study: A Potential Game-Changer in Cardiovascular Treatment

First patient enrolled in EASE HF2 study of Intershunt technology for HFrEF treatment - Cardiovascular News

InterShunt Technologies has announced the start of the EASE HF2 early feasibility study, which is evaluating a device designed to reduce heart failure symptoms and improve quality of life. The first US procedure utilising InterShunt’s technology was performed by Sitaramesh Emani and the Structural Heart Intervention team at The Christ Hospital Health Network (Cincinnati, USA). “We’re excited to get this study started,” said Emani. “The first pro…